McCarthy Cian P, Yousuf Omair, Alonso Alvaro, Selvin Elizabeth, Calkins Hugh, McEvoy John W
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Am J Cardiol. 2017 May 1;119(9):1407-1413. doi: 10.1016/j.amjcard.2017.01.032. Epub 2017 Feb 9.
Biomarkers are important prognostic tools in various cardiovascular conditions, including coronary artery disease and heart failure. Although their utility in cardiac electrophysiology (EP) is less established, biomarkers may guide EP clinical practice by identifying patients at risk for developing arrhythmias and their complications, in addition to augmenting therapeutic decisions by targeting appropriate pharmacologic and interventional therapies to patients who may benefit most. In this review, we focus on the prognostic role of high-sensitivity cardiac troponin (hs-cTn) assays-which detect subclinical cardiac myocyte damage-in cardiac arrhythmias and their sequelae. We review the current literature on hs-cTn and its impact on various arrhythmia disease states and also provide suggestions for future research in this field. In conclusion, although the utility of hs-cTn assays remains at an investigational stage in cardiac EP, studies to date have suggested value as a prognostic biomarker in atrial fibrillation and as a screening marker for patients at high risk of sudden cardiac death (both in the general population and among those with hypertrophic cardiomyopathy).
生物标志物是包括冠状动脉疾病和心力衰竭在内的各种心血管疾病中重要的预后工具。尽管它们在心脏电生理学(EP)中的应用尚未完全确立,但生物标志物除了通过针对可能最受益的患者进行适当的药物和介入治疗来增强治疗决策外,还可以通过识别有发生心律失常及其并发症风险的患者来指导EP临床实践。在本综述中,我们重点关注高敏心肌肌钙蛋白(hs-cTn)检测——检测亚临床心肌细胞损伤——在心律失常及其后遗症中的预后作用。我们回顾了关于hs-cTn的现有文献及其对各种心律失常疾病状态的影响,并为该领域的未来研究提供建议。总之,尽管hs-cTn检测在心脏EP中的应用仍处于研究阶段,但迄今为止的研究表明,它作为心房颤动的预后生物标志物以及心脏性猝死高危患者(包括普通人群和肥厚型心肌病患者)的筛查标志物具有价值。